<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916785</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT 2008-006854-17</org_study_id>
    <nct_id>NCT01916785</nct_id>
  </id_info>
  <brief_title>OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)</brief_title>
  <acronym>OPTIM-DASA</acronym>
  <official_title>A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Versailles Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maisonneuve-Rosemont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Versailles Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol is a multicentric interventional phase II study from the French CML Intergroup
      (FILMC).

      The core of the protocol is to explore the efficacy and safety of an optimization strategy
      consisting in the modulation of the dasatinib daily dose according to the results of repeated
      plasmatic levels of dasatinib.

      The objective of this strategy is to improve the overall results of the treatment of early
      CP-CML in order to avoid the development of resistance and BCR-ABL tyrosine kinase mutations.

      The study will be conducted in selected FILMC and Canadian centers.

      The study is sponsored by the Hôpitaux de Versailles and supported by Bristol-Myers Squibb.
      The dasatinib treatment will be provided by Bristol-Myers Squibb until marketing
      authorization is granted in that indication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative rate of significant AE</measure>
    <time_frame>12 months therapy</time_frame>
    <description>The cumulative rate of serious AEs defined by grade 3-4 fluid retention, all grade pleural effusion, haematological grade 3-4 AEs related to dasatinib and/or all AE leading to dasatinib discontinuation within the first year of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of treatment interruptions</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the rate of treatment interruptions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative duration of dasatinib interruption</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the cumulative duration of dasatinib interruption C. To compare the median dose of dasatinib administered during the first 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean dose of dasatinib</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the mean dose of dasatinib administered during the first 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of complete cytogenetic response</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the cumulative rate of complete cytogenetic response (CCR) at 6, 12 and 18 months, and every 12 months thereafter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of major molecular response</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the cumulative rate of major molecular response (MMR) at 3, 6, 12, and 18 months, and every 6 months thereafter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median dose of dasatinib administered</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the median dose of dasatinib administered during the first 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative rate of complete molecular response</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the cumulative rate of complete molecular response at 3, 6, 12 and 18 months, and every 6 months thereafter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to molecular response</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the time to molecular response (major or complete)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between peak plasmatic level and efficacy</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To analyse the relationship between peak plasmatic level (Cmax) and efficacy in the three arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between through plasmatic level and efficacy</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To analyse the relationship between through plasmatic level (Cmin) and efficacy in the three arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival at 5 years</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the progression-free survival (PFS) at 5 years in the three arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival at 5 years</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To compare the overall survival at 5 years in the three arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte populations before and during dasatinib therapy</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To analyse lymphocyte populations before and during dasatinib therapy (for French participating centers - see appendix 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of sustained major molecular remission after dasatinib discontinuation in patients in complete molecular response</measure>
    <time_frame>12 months therapy</time_frame>
    <description>To evaluate the rate of sustained major molecular remission after dasatinib discontinuation in patients in complete molecular response, CMR (undetectable BCR-ABL transcript, BCR-ABL/ABL IS ratio &lt; 1x10-5)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Chronic Myelogenous Leukemia, BCR/ABL Positive</condition>
  <arm_group>
    <arm_group_label>A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A1: Dasatinib dose adjustment based on Cmin ≥3nM value analysed on blood after 7-10 days dasatinib 100mg intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm A2: Dasatinib standard dose (100mg/d) with Cmin ≥ 3nM analysed on blood after 7-10 days dasatinib 100mg intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B : Dasatinib standard dose with Cmin &lt; 3nM analysed on blood after 7-10 days dasatinib 100mg intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate</description>
    <arm_group_label>A1</arm_group_label>
    <arm_group_label>A2</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Sprycel®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient ≥ 18 years

          2. ECOG Performance Status score 0-2

          3. Philadelphia chromosome positive newly diagnosed (≤ 3 months) CP-CML

          4. patients not previously treated except with hydroxyurea or imatinib (less than 4 weeks
             for imatinib)

          5. Signed written inform consent

          6. Adequate hepatic function defined as: total bilirubin ≤ 2.0 times the institutional
             ULN; ALT and AST ≤ 2.5 times the institutional upper limit of normal (ULN).

          7. Adequate renal function defined as serum creatinine ≤ 3 times the institutional ULN.

          8. Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception.

        Exclusion Criteria:

          1. Patients with BCR-ABL positive, Philadelphia negative CML

          2. Patient previously treated with a tyrosine kinase inhibitor (TKI) except with imatinib
             during less than 4 weeks.

          3. Pregnancy

          4. Active malignancy

          5. Uncontrolled or significant cardiovascular disease

          6. Patients with QTc &gt; 450 ms

          7. Significant bleeding disorder unrelated to CML

          8. Concurrent severe diseases which exclude the administration of therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe ROUSSELOT, Professeur hémato-oncologie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Versailles Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern Alberta Cancer Research Institute</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen elisabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Pierre LeGardeur</name>
      <address>
        <city>Lachenaie</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton City Hospital</name>
      <address>
        <city>Moncton</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Général Juif - Sir. Mortimer B. Davis</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Royal Victoria</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Enfant Jésus - Centre hospitalier affilié universitaire de Québec</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavillon Hôtel-Dieu de Québec - Centre hospitalier universitaire de Québec</name>
      <address>
        <city>Québec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital MORVAN</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Cergy Pontoise</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction de Armées Percy</name>
      <address>
        <city>Clamart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Henri MONDOR</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Annecy</name>
      <address>
        <city>Metz Tessy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.U. Brabois</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hoptel dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet 1</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>Nimes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Rennes - Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Bretonneau</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Versailles Hospital</investigator_affiliation>
    <investigator_full_name>Philippe ROUSSELOT</investigator_full_name>
    <investigator_title>Clinical Coordinator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

